

## Review information

### Authors

[Empty name]<sup>1</sup>

<sup>1</sup>[Empty affiliation]

Citation example: [Empty name]. [Serotonine Reuptake Inhibitors] for [Fibromyalgia syndrome]. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

## Characteristics of studies

### Characteristics of included studies

#### *Anderberg 2000 Ci 20-40mg*

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

### Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

#### *Arnold 2002 Fluo 10-80 mg*

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Ataoglu 1997 Paro 20mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Capaci 2002 Paro 20-40mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Glaxo 1995 Paro 20 mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Goldenberg 1996 Fluo 20mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

***Gonzales 2005 Sertr 50mg***

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

***Gülec 2007 VLXF 75mg***

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Hussain 2010 Fluo 20mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

**Noregaard 1995 Ci 20 mg**

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

***Patkar 2007 Paro 62.5 mg***

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

## Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

***Sencan 2004 Paro 20 mg***

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

### Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

### *Wolfe 1994 Fluo 20 mg*

<b>Methods</b>	
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Notes</b>	

### Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Allocation concealment (selection bias)	Unclear risk	

### Footnotes

## **Characteristics of excluded studies**

*Footnotes*

## **Characteristics of studies awaiting classification**

*Footnotes*

## **Characteristics of ongoing studies**

*Footnotes*

## **References to studies**

### **Included studies**

***Anderberg 2000 Ci 20-40mg***

[Empty]

***Arnold 2002 Fluo 10-80 mg***

[Empty]

***Ataoglu 1997 Paro 20mg***

[Empty]

***Capaci 2002 Paro 20-40mg***

[Empty]

***Glaxo 1995 Paro 20 mg***

[Empty]



**Goldenberg 1996 Fluo 20mg**

[Empty]

**Gonzales 2005 Sertr 50mg**

[Empty]

**Gülec 2007 VLXF 75mg**

[Empty]

**Hussain 2010 Fluo 20mg**

[Empty]

**Noregaard 1995 Ci 20 mg**

[Empty]

**Patkar 2007 Paro 62.5 mg**

[Empty]

**Sencan 2004 Paro 20 mg**

[Empty]

**Wolfe 1994 Fluo 20 mg**

[Empty]

**Excluded studies****Data and analyses****1 SSRI versus Placebo**


Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
---------------------	---------	--------------	--------------------	-----------------

1.1 Pain	7	322	Std. Mean Difference (IV, Random, 95% CI)	-0.40 [-0.73, -0.07]
1.1.1 Mean	3	108	Std. Mean Difference (IV, Random, 95% CI)	-0.50 [-1.10, 0.09]
1.1.2 Mean change	4	214	Std. Mean Difference (IV, Random, 95% CI)	-0.33 [-0.76, 0.09]
1.2 Fatigue	5	193	Std. Mean Difference (IV, Random, 95% CI)	-0.17 [-0.46, 0.11]
1.2.1 Mean	2	65	Std. Mean Difference (IV, Random, 95% CI)	-0.13 [-0.63, 0.36]
1.2.2 Mean change	3	128	Std. Mean Difference (IV, Random, 95% CI)	-0.19 [-0.62, 0.25]
1.3 Sleep	5	185	Std. Mean Difference (IV, Random, 95% CI)	-0.31 [-0.60, -0.02]
1.3.1 Mean	3	108	Std. Mean Difference (IV, Random, 95% CI)	-0.32 [-0.70, 0.06]
1.3.2 Mean change	2	77	Std. Mean Difference (IV, Random, 95% CI)	-0.29 [-0.74, 0.16]
1.4 Depressed mood	6	236	Std. Mean Difference (IV, Random, 95% CI)	-0.34 [-0.60, -0.08]
1.4.1 Mean	3	108	Std. Mean Difference (IV, Random, 95% CI)	-0.27 [-0.65, 0.11]
1.4.2 Mean change	3	128	Std. Mean Difference (IV, Random, 95% CI)	-0.40 [-0.83, 0.03]
1.5 Quality of life	3	208	Std. Mean Difference (IV, Random, 95% CI)	-0.47 [-0.84, -0.10]
1.5.1 Mean	1	41	Std. Mean Difference (IV, Random, 95% CI)	-0.57 [-1.20, 0.05]
1.5.2 Mean change	2	167	Std. Mean Difference (IV, Random, 95% CI)	-0.47 [-1.04, 0.11]
1.6 Total Drop out	7	414	Risk Ratio (M-H, Random, 95% CI)	1.36 [0.79, 2.36]
1.7 30% pain reduction	7	392	Risk Ratio (M-H, Random, 95% CI)	1.59 [1.01, 2.52]
1.8 SDrop out to AEs	5	291	Risk Ratio (IV, Random, 95% CI)	1.32 [0.58, 3.02]
1.9 Nausea	4	240	Risk Ratio (M-H, Random, 95% CI)	1.40 [0.82, 2.40]
1.10 Headache	3	200	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.46, 1.88]
1.11 Sexual dysfunction	2	158	Risk Ratio (M-H, Random, 95% CI)	9.51 [1.22, 73.99]


1.12 Sleep problems	3	210	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.15, 9.80]
1.13 Function FIQ physical function, change	1	51	Mean Difference (IV, Fixed, 95% CI)	-0.70 [-1.91, 0.51]

## Figures

Figure 1 (Analysis 1.1)




Forest plot of comparison: 1 SSRI versus Placebo, outcome: 1.1 Pain.

**Figure 2 (Analysis 1.2)**


Forest plot of comparison: 1 SSRI versus Placebo, outcome: 1.2 Fatigue.

**Figure 3 (Analysis 1.3)**




Forest plot of comparison: 1 SSRI versus Placebo, outcome: 1.3 Sleep.

**Figure 4 (Analysis 1.5)**



Forest plot of comparison: 1 SSRI versus Placebo, outcome: 1.5 Quality of life.

**Figure 5 (Analysis 1.4)**



Forest plot of comparison: 1 SSRI versus Placebo, outcome: 1.4 Depressed mood.